Viatris, formed from the 2020 merger of Mylan and Pfizer's Upjohn division, is a global pharmaceutical company focused on generic, branded, and biosimilar medicines. The investment thesis centers on its deep value characteristics " the stock trades at a significant discount to peers on P/E and EV/EBITDA metrics, reflecting market skepticism about its growth trajectory. The company has made progress deleveraging its balance sheet through asset divestitures, including selling its biosimilar portfolio and OTC business, using proceeds to reduce debt. Viatris offers an attractive dividend yield, appealing to income-oriented investors. However, the bear case is substantial: the core generics business faces persistent pricing erosion, revenue has been declining organically, and the new product pipeline must consistently deliver to offset base business erosion. Management's pivot toward higher-growth branded products through acquisitions like Oyster Point and Famy Life Sciences signals strategic ambition but introduces execution risk. For patient value investors comfortable with pharmaceutical industry headwinds, Viatris offers a compelling risk-reward at current valuations, though catalysts for re-rating remain uncertain.